Document Detail

Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects.
MedLine Citation:
PMID:  21290185     Owner:  NLM     Status:  MEDLINE    
Disorders of branched-chain amino/keto acid metabolism encompass diverse entities, including maple syrup urine disease (MSUD), the 'classical' organic acidurias isovaleric acidemia (IVA), propionic acidemia (PA), methylmalonic acidemia (MMA) and, among others, rarely described disorders such as 2-methylbutyryl-CoA dehydrogenase deficiency (MBDD) or isobutyryl-CoA dehydrogenase deficiency (IBDD). Our focus in this review is to highlight the biochemical basis underlying recent advances and ongoing challenges of long-term conservative therapy including precursor/protein restriction, replenishment of deficient substrates, and the use of antioxidants and anaplerotic agents which refill the Krebs cycle. Ongoing clinical assessments of affected individuals in conjunction with monitoring of disease-specific biochemical parameters remain essential. It is likely that mass spectrometry-based 'metabolomics' may be a helpful tool in the future for studying complete biochemical profiles and diverse metabolic phenotypes. Prospective studies are needed to test the effectiveness of adjunct therapies such as antioxidants, ornithine-alpha-ketoglutarate (OKG) or creatine in addition to specialized diets and to optimize current therapeutic strategies in affected individuals. With the individual life-time risk and degree of severity being unknown in asymptomatic individuals with MBDD or IBDD, instructions regarding risks for metabolic stress and fasting avoidance along with clinical monitoring are reasonable interventions at the current time. Overall, it is apparent that carefully designed prospective clinical investigations and multicenter cohort-controlled trials are needed in order to leverage that knowledge into significant breakthroughs in treatment strategies and appropriate approaches.
Ina Knerr; Natalie Weinhold; Jerry Vockley; K Michael Gibson
Related Documents :
21290185 - Advances and challenges in the treatment of branched-chain amino/keto acid metabolic de...
22615405 - Reprogramming of proline and glutamine metabolism contributes to the proliferative and ...
23287075 - Incorporation and mineralization of tnt and other anthropogenic organics by natural mic...
24937255 - Fed state prior to hemorrhagic shock and polytrauma in a porcine model results in alter...
3281885 - Reduction by prostacyclin of acetaminophen-induced liver toxicity in the mouse.
17303475 - Peripheral serotonin dynamics in the rainbow trout (oncorhynchus mykiss).
Publication Detail:
Type:  Journal Article; Review     Date:  2011-02-03
Journal Detail:
Title:  Journal of inherited metabolic disease     Volume:  35     ISSN:  1573-2665     ISO Abbreviation:  J. Inherit. Metab. Dis.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-01-02     Completed Date:  2012-05-25     Revised Date:  2014-08-21    
Medline Journal Info:
Nlm Unique ID:  7910918     Medline TA:  J Inherit Metab Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  29-40     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acid Metabolism, Inborn Errors / therapy*
Amino Acids, Branched-Chain / metabolism*
Creatinine / metabolism
Maple Syrup Urine Disease / diagnosis*
Mass Spectrometry / methods
Metabolomics / methods
Mice, Knockout
Mice, Transgenic
Ornithine / analogs & derivatives,  metabolism
Grant Support
Reg. No./Substance:
0/Amino Acids, Branched-Chain; 37339-58-5/ornithine alpha-ketoglutarate; AYI8EX34EU/Creatinine; E524N2IXA3/Ornithine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Features and outcome of galactokinase deficiency in children diagnosed by newborn screening.
Next Document:  Parenting a child with phenylketonuria or galactosemia: implications for health-related quality of l...